

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No

Note: During the development of TA255, the Committee understood that people who have proposed, started or completed male to female gender reassignment can develop prostate cancer. The Committee therefore concluded that this appraisal should refer to people rather than to men.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?

N/A

4. Have any additional stakeholders related to potential equality issues

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)

Issue date: July 2015

been identified during the scoping process, and, if so, have changes to the matrix been made?
---

No
----

**Approved by Associate Director (name):** Melinda Goodall

**Date:** 27/07/2015